A Phase 3 interventional study of Cagrilintide and Semaglutide in Overweight, Obesity and Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S. Completed at 179 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.
Among the 36 studies testing cagrilintide in Obesity, this one is the 4th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 3, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Greece, Hungary and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–64
Novo Nordisk A/S · Sites in Germany
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,200 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 154 across the 36 interventional studies. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 12th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 62 in phase 3, and was the 89th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
8 of the studies testing cagrilintide in Obesity that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07557953Novo Nordisk A/SA Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | 2027-04-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies testing cagrilintide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 1,200 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cagrilintide + semaglutide once weekly
Drug: Cagrilintide · Drug: Semaglutide
Placebo cagrilintide + semaglutide once weekly
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Relative change in body weight
Measured in percentage (%).
Time frame: From baseline (week 0) to end of treatment (week 68)
Achievement of greater than or equal to (≥) 5% weight reduction
Count of participant.
Time frame: From baseline (week 0) to end of treatment (week 68)
Achievement of ≥ 20% weight reduction
Count of participant.
Time frame: From baseline (week 0) to end of treatment (week 68)
Relative change in body weight
Measured in %.
Time frame: From baseline (week 0) to week 20
Change in waist circumference
Measured in centimeter (cm).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Glycated Haemoglobin (HbA1c)
Measured in %-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Systolic Blood Pressure (SBP)
Measured in millimeter of mercury (mmHg).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score
Measured in score points.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Short Form-36 Version 2.0 Health Survey Acute (SF-36v2 Acute) Physical Functioning score
Measured in score points.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in body weight
Measured in kilogram (kg).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in body mass index (BMI)
Measured in kilogram per meter square (kg/m\^2).
Time frame: From baseline (week 0) to end of treatment (week 68)
Improvement in weight category (BMI, underweight below 18.5, normal weight 18.5 to below 25, overweight 25.0 to below 30, obesity class I 30 to below 35, obesity class II 35 to below 40, obesity class III above 40)
Count of participant.
Time frame: From baseline (week 0) to end of treatment (week 68)
Achievement of HbA1c less than or equal to (≤) 6.5%
Count of participant.
Time frame: At end of treatment (week 68)
Change in Fasting Plasma Glucose (mmol/L)
Measured in millimoles per liter (mmol/L).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Fasting Plasma Glucose (mg/dL)
Measured in milligram per deciliter (mg/dL)
Time frame: From baseline (week 0) to end of treatment (week 68)
Ratio to baseline in fasting serum insulin
Measured in ratio.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Diastolic Blood Pressure (DBP)
Measured in mmHg.
Time frame: From baseline (week 0) to end of treatment (week 68)
Ratio to baseline in C-reactive protein (CRP)
Measured in ratio.
Time frame: From baseline (week 0) to end of treatment (week 68)
Ratio to baseline in lipids: Total cholesterol, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol, Triglycerides and Free fatty acids
Measured in ratio.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in IWQOL-Lite-CT: Total score, Physical and Psycosocial score
IWQOL-Lite-CT is a 20-item clinical outcomes assessment (COA) instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. Score ranges for composite score (physical composite, psychosocial composite and physical function composite) and Total score is 0-100. Higher scores indicate better level of functioning.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Control of Eating Questionnaire (CoEQ): Craving Control score, Positive Mood score, Craving for Sweet score, Craving for Savoury food score, Hunger score and Satiety score
CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). Higher score represents a greater level of Craving Control.
Time frame: From baseline (week 0) to end of treatment (week 68)
Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score
Count of participant.
Time frame: From baseline (week 0) to end of treatment (week 68)
Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Acute Physical Functioning score
Count of participant.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in IWQOL-Lite-CT Physical Function score
Time frame: From baseline (week 0) to end of treatment (week 68)
Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite -CT Physical Function score for subgroup
Count of participant.
Time frame: From baseline (week 0) to end of treatment (week 68)
Continuous glucose monitoring: Change in mean glucose (mmol/L)
Measured in mmol/L.
Time frame: From baseline (week 0) to end of treatment (week 68)
Continuous glucose monitoring: Change in mean glucose (mg/L)
Measured in mg/L.
Time frame: From baseline (week 0) to end of treatment (week 68)
CGM: Change in time above range (TAR) >10.0 mmol/L (>180 mg/dL)
Measured in %-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Measured in %-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CGM: Change in time above high range (TAHR) >13.9 mmol/L (>250 mg/dL)
Measured in %-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CGM: Change in time in tight range (TITR) 3.9-7.8 mmol/L (71-140 mg/dL)
Measured in %-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CGM: Within-day glycaemic variability (% CV)
Measured in %.
Time frame: At end of treatment (week 68)
Number of Treatment Emergent Adverse Events (TEAEs)
Count of events.
Time frame: From baseline (week 0) to end of study (week 75)
Number of Treatment Emergent Serious adverse events (TESAEs)
Count of events.
Time frame: From baseline (week 0) to end of study (week 75)
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Count of episodes.
Time frame: From baseline (week 0) to end of study (week 75)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Count of episodes.
Time frame: From baseline (week 0) to end of study (week 75)
Showing the first 100 of 179 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"
Data sharing details ↗ · novonordisk-trials.com
Ran from Feb 2023 to primary completion in Jan 2025, 23 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 23 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide